Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
$1.18
+3.5%
$1.91
$0.39
$18.00
$5.60M3.523,850 shs618 shs
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
$0.09
+21.4%
$0.50
$0.05
$23.40
$470K1.31.37 million shs77,846 shs
Neovasc Inc. stock logo
NVCN
Neovasc
$30.03
$29.69
$4.59
$30.07
$82.28M1.756,993 shs1 shs
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
+3.51%+1.72%-44.86%-71.15%-63.13%
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
+10.00%+1.32%-83.26%-91.78%-99.37%
Neovasc Inc. stock logo
NVCN
Neovasc
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
1.1885 of 5 stars
3.53.00.00.00.60.00.6
Neovasc Inc. stock logo
NVCN
Neovasc
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
N/AN/AN/AN/A
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
3.00
Buy$28.8830,782.35% Upside
Neovasc Inc. stock logo
NVCN
Neovasc
N/AN/AN/AN/A

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
$80K69.94N/AN/A($2.43) per share-0.49
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
$319K1.47N/AN/A$1.74 per share0.05
Neovasc Inc. stock logo
NVCN
Neovasc
$3.81M21.60N/AN/A$5.77 per share5.20

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
-$6.98MN/A0.00N/A-6,809.45%N/A-386.74%5/20/2024 (Estimated)
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
-$12.87M-$28.55N/AN/A-4,033.54%N/A-110.70%5/8/2024 (Estimated)
Neovasc Inc. stock logo
NVCN
Neovasc
-$41.20M-$15.08N/AN/A-1,082.92%-127.25%-80.31%N/A

Latest NVCN, ARTH, and MOTS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/18/2024Q4 2023
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
N/A-$4.13-$4.13-$3.78N/A$0.06 million
2/20/2024Q1 2024
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
N/A-$0.57-$0.57-$0.57N/A$0.05 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
N/AN/AN/AN/AN/A
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
N/AN/AN/AN/AN/A
Neovasc Inc. stock logo
NVCN
Neovasc
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
N/A
0.16
0.04
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
0.46
1.76
1.69
Neovasc Inc. stock logo
NVCN
Neovasc
0.80
2.96
2.85

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
6.91%
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
20.06%
Neovasc Inc. stock logo
NVCN
Neovasc
1.64%

Insider Ownership

CompanyInsider Ownership
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
4.50%
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
1.57%
Neovasc Inc. stock logo
NVCN
Neovasc
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
84.74 million4.53 millionNot Optionable
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
155.03 million4.95 millionNot Optionable
Neovasc Inc. stock logo
NVCN
Neovasc
492.74 millionN/ANot Optionable

NVCN, ARTH, and MOTS Headlines

SourceHeadline
Top Small-Cap Stocks for May 2023 - InvestopediaTop Small-Cap Stocks for May 2023 - Investopedia
news.google.com - May 13 at 9:38 AM
FDA accepts application for Roches Vabysmo for the - GlobeNewswireFDA accepts application for Roche's Vabysmo for the - GlobeNewswire
news.google.com - May 9 at 2:18 AM
New treatment option opens avenues in geographic atrophy - HealioNew treatment option opens avenues in geographic atrophy - Healio
news.google.com - May 8 at 9:18 PM
Pachychoroid neovasculopathy has clinical properties that differ ... - Nature.comPachychoroid neovasculopathy has clinical properties that differ ... - Nature.com
news.google.com - May 8 at 9:18 PM
The NOD audit provides data and insights for the management for ... - Modern RetinaThe NOD audit provides data and insights for the management for ... - Modern Retina
news.google.com - May 8 at 9:18 PM
Shockwave Medical Reports First Quarter 2023 Financial Results - GlobeNewswireShockwave Medical Reports First Quarter 2023 Financial Results - GlobeNewswire
news.google.com - May 8 at 4:17 PM
Heart valve repair and replacement devices market size to grow by ... - BenzingaHeart valve repair and replacement devices market size to grow by ... - Benzinga
news.google.com - May 5 at 9:03 PM
ASCRS: Prediction of imminent conversion to neovascular AMD ... - Optometry TimesASCRS: Prediction of imminent conversion to neovascular AMD ... - Optometry Times
news.google.com - May 5 at 4:02 PM
Faricimab in Treatment-Resistant nARMD | OPTH - Dove Medical PressFaricimab in Treatment-Resistant nARMD | OPTH - Dove Medical Press
news.google.com - May 5 at 12:24 AM
Restoring vision through retinal ganglion cell repopulation - Ophthalmology Times EuropeRestoring vision through retinal ganglion cell repopulation - Ophthalmology Times Europe
news.google.com - May 5 at 12:24 AM
STAR Trial: Surgery Not Superior to Pneumatic Displacement for ... - MD MagazineSTAR Trial: Surgery Not Superior to Pneumatic Displacement for ... - MD Magazine
news.google.com - May 4 at 7:24 PM
The NOD audit: Insights into the current state of management for ... - Nature.comThe NOD audit: Insights into the current state of management for ... - Nature.com
news.google.com - May 4 at 8:40 AM
On the horizon: Treatments for both forms of AMD - Ophthalmology Times EuropeOn the horizon: Treatments for both forms of AMD - Ophthalmology Times Europe
news.google.com - May 3 at 10:56 AM
Biosimilar Ranibizumab Displays Comparable Safety, Efficacy to ... - The Center for BiosimilarsBiosimilar Ranibizumab Displays Comparable Safety, Efficacy to ... - The Center for Biosimilars
news.google.com - April 28 at 3:22 PM
Real World Evidence Supporting GA Therapy Management Strategies - AJMC.com Managed Markets NetworkReal World Evidence Supporting GA Therapy Management Strategies - AJMC.com Managed Markets Network
news.google.com - April 28 at 10:22 AM
Low-vision services improve vision, quality of life in patients with ... - HealioLow-vision services improve vision, quality of life in patients with ... - Healio
news.google.com - April 28 at 10:22 AM
New Vabysmo data suggest greater retinal drying versus aflibercept ... - GlobeNewswireNew Vabysmo data suggest greater retinal drying versus aflibercept ... - GlobeNewswire
news.google.com - April 25 at 6:55 PM
New treatment tackles both forms of AMD - Ophthalmology TimesNew treatment tackles both forms of AMD - Ophthalmology Times
news.google.com - April 25 at 6:55 PM
Price Variation in Economic Evaluations of Infliximab Could ... - The Center for BiosimilarsPrice Variation in Economic Evaluations of Infliximab Could ... - The Center for Biosimilars
news.google.com - April 25 at 1:32 AM
1-Year Outcomes of Phase 3 Study for SB15, Proposed biosimilar to Eylea (aflibercept), Presented at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting - Yahoo Finance1-Year Outcomes of Phase 3 Study for SB15, Proposed biosimilar to Eylea (aflibercept), Presented at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting - Yahoo Finance
news.google.com - April 25 at 1:32 AM
Accel Research expands reach with acquisition of two Florida trial ... - FierceBiotechAccel Research expands reach with acquisition of two Florida trial ... - FierceBiotech
news.google.com - April 24 at 3:16 PM
Report: Boston Scientific considering massive deal to acquire ... - Cardiovascular BusinessReport: Boston Scientific considering massive deal to acquire ... - Cardiovascular Business
news.google.com - April 24 at 3:16 PM
Boston Sci Rumored to Be Interested in Acquiring Shockwave - Medical Device and Diagnostics IndustryBoston Sci Rumored to Be Interested in Acquiring Shockwave - Medical Device and Diagnostics Industry
news.google.com - April 21 at 4:24 PM
The Future of the Structural Heart Disease Intervention Devices ... - Digital JournalThe Future of the Structural Heart Disease Intervention Devices ... - Digital Journal
news.google.com - April 21 at 10:58 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Arch Therapeutics logo

Arch Therapeutics

OTCMKTS:ARTH
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.
Motus GI logo

Motus GI

NASDAQ:MOTS
Motus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. The company was founded in 2008 and is based in Fort Lauderdale, Florida.
Neovasc logo

Neovasc

NASDAQ:NVCN
Neovasc, Inc. engages in the development, manufacture and marketing of medical devices. It focuses on Neovast Tiara and Neovasc Reducer products. The company was founded on November 2, 2000 and is headquartered in Richmond, Canada.